Moreover, genes linked to Vitamin D metabolism, such as CYP27B1, CYP24A1, and genes coding for targets of MS immune-modulatory therapies, including VCAM1 for natalizumab and IL2RA for daclizumab, were also highlighted. This evidence concerns the gene IL2RA and myeloid sarcoma.